Drug-Coated Balloon Angioplasty for Dysfunctional Arteriovenous Hemodialysis Fistulae

Author:

Zhao Yiping1,Wang Pei2ORCID,Wang Yuzhu3ORCID,Zhang Lihong4,Zhao Yu5ORCID,Li Hua6,He Qiang7,Liu Hao8ORCID,Luo Jianfang9,Jia Xin10,Yu Zhengya11ORCID,Guo Wei10ORCID,Zhang Lan1

Affiliation:

1. Vascular Surgery Department, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai Jiaotong University, Shanghai, China

2. Blood Purification Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China

3. Nephrology Department, Beijing Haidian Hospital, Beijing, China

4. Nephrology Department, The First Hospital of Hebei Medical University, Hebei Medical University, Shijiazhuang, China

5. Vascular Surgery Department, The First Affiliated Hospital of Chongqing Medical University, Chongqing Medical University, Chongqing, China

6. Nephrology Department, Shaoyifu Hospital, Zhejiang Medical University, Hangzhou, China

7. Nephrology Department, Zhejiang Provincial People's Hospital, Hangzhou, China

8. Vascular and Interventional Radiology Department, Nanfang Hospital, Southern Medical University, Guangzhou, China

9. Cardiology Department, Guangdong Provincial People's Hospital, Guangzhou, China

10. Vascular Surgery Department, Chinese PLA General Hospital, Beijing, China

11. Vascular Surgery Department, Tongren Hospital, Capital Medical University, Beijing, China

Abstract

Background The aim of this study was to evaluate the efficacy and safety of paclitaxel-coated balloons (AcoArt Orchid) in treating dysfunctional arteriovenous fistulae. Methods The drug-eluting balloon for arteriovenous (AV) fistula in China trial was a prospective, multicenter, randomized controlled study. Patients who had ≥50% venous stenosis of the AV fistula and symptoms indicating significant hemodynamic changes were included. After successful predilation with a high-pressure balloon (residual stenosis ≤30%), patients were randomized 1:1 to either a paclitaxel-coated balloon or an uncoated control balloon. The primary efficacy outcome was assessed at 6 months, and safety assessment was conducted within 30 days of the procedure. The 12-month results were also analyzed. Results The study included 244 patients, equally distributed between the two groups. The primary target lesion patency was 91% (106/116) for the drug-coated balloon (DCB) group and 67% (79/118) for the plain balloon catheter group, representing a difference of 24.63% (95% confidence interval, 14.68 to 34.58; P < 0.001). The secondary efficacy end point was primary target lesion patency at 12 months, which was 66% (74/112) for the DCB group and 46% (52/112) for the plain balloon catheter group (95% confidence interval, 6.57 to 32.08; P = 0.004). The mean number of reinterventions per patient to maintain target lesion patency during the 12 months after the index procedure was 0.39 (48/122) in the DCB group and 0.77 (94/122) in the plain balloon catheter group (P = 0.001). The primary safety end point did not differ between groups (P = 0.25). Conclusions AcoArt Orchid DCB showed better primary patency rates compared with plain balloon angioplasty for treating stenotic lesions in dysfunctional hemodialysis AV fistulae at 6 and 12 months. It required fewer repeated interventions and had comparable safety in 1 year. Clinical Trial registry name and registration number AcoArt III/Arterio-venous Fistula in China, NCT03366727.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Transplantation,Nephrology,Critical Care and Intensive Care Medicine,Epidemiology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3